In addition, in melanoma, it appears that oncogenic BRAF-signaling may cloak immune antigens present on the cancer cells and that treating with BRAFV600E-inhibitors promotes anti-tumor immune cell infiltration and activity [15-21]. The gene discussed is BRAF; the disease is neoplasm.